Insulet Corporation is a medical device company that develops, manufactures, and sells continuous insulin delivery systems for people with insulin-dependent diabetes. Its primary product line is the Omnipod platform, which includes the Omnipod 5 Automated Insulin Delivery System, the Omnipod DASH Insulin Management System, and the Classic Omnipod. These tubeless, wearable, and disposable Pod devices provide continuous subcutaneous insulin infusion without external tubing. The Omnipod 5 features an embedded automated insulin delivery algorithm that integrates with third-party continuous glucose monitors, such as Dexcom and Abbott sensors, to automatically adjust insulin dosing. The company also produces insulin pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Neulasta to reduce infection risk after chemotherapy. Insulet serves patients in North America, Europe, the Middle East, and Asia Pacific. The company was founded in 2000.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage insulet.com
Sector Healthcare IR page investors.insulet.com/overview/default.aspx
Tags
diabetes management, insulin delivery, automated insulin delivery, continuous glucose monitoring integration, tubeless insulin pumps, wearable medical devices, oncology support, Omnipod, Omnipod 5, Omnipod DASH, Classic Omnipod, Neulasta Onpro, Neulasta, Dexcom, Abbott, FreeStyle Libre 2 Plus, Amgen
Press page —

Metrics

Valuation  
Market cap $ 9.051B
Market cap (USD) $ 9.051B
P/E 21.32
PEG 0.08
P/BV 5.73
P/S 2.84
P/OCF 17.78
P/FCF 34.81
Dividend yield —
Turnover / mcap —
Returns  
ROE 18.1%
ROI 10.0%
ROIC 14.0%
Profit margin 9.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 277.3%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 62.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 42
Quality score 11.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Revenue 2.708B 2.072B 1.697B 1.055B 1.099B 904.4M 738.2M 563.823M 463.768M 366.989M 324.225M 288.72M 247.084M 211.369M 152.255M 96.966M 36.059M 36.059M 13.372M 3.663M
Net profit 247.1M 418.3M 206.3M 4.6M 16.8M 6.8M 11.6M 3.292M -26.831M -28.879M -73.52M -51.5M -44.974M -51.867M -57.17M -61.159M -94.771M -92.791M -53.539M -35.95M
Free cash flow 377.7M 305.4M 70.1M -3.9M -180M -45M -65.3M -126.455M -36.019M -6.204M -23.16M -2.566M -3.959M -40.05M -36.566M -42.174M -92.658M -92.658M -5.408M -10.716M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006
Share price 284.24 261.07 216.98 294.39 266.07 255.63 171.2 79.32 69 37.68 37.81 46.06 37.1 21.22 19.26 15.58 14.74 4.4 23.14 —
Price performance 12m 0.09 0.2 -0.26 0.11 0.04 0.49 1.16 0.15 0.83 -0 -0.18 0.24 0.75 0.1 0.24 0.06 2.35 -0.81 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 28.8M 53.4M 63.3M 69.3M 83.8M 161M 141M — — 517M
↳ YoY growth -40.5% +85.3% +18.6% +9.5% +20.9% +92.1% -12.5%
↳ 5y CAGR +4.4% +9.9% +13.9% +11.7% +11.6% +41.1% +21.4% +43.9%
Borrowings, current (USD) — 0.00 — 0.00 15.6M 25.1M 27.5M 49.4M 83.8M 18.4M
Borrowings, non-current (USD) 333M 566M 592M 888M 1.04B 1.25B 1.37B 1.37B 1.3B 931M
Lease liabilities (USD) — — — 18M 16.9M 12.6M 31M 78.8M 42.1M 51.9M
Cash and deposits (USD) 137M 273M 114M 214M 907M 806M 690M 704M 953M 716M
Intangible assets (USD) 528,000 4.35M 10.4M 13.2M 28.7M 36.6M 75.5M 98.7M 98.5M 117M
Right-of-use assets (USD) — — — 16.1M 14.9M 9.9M 26M 27.9M 36.7M 43.7M
Net debt (borrowings + leases - cash) (USD) 196M 294M 478M 692M 169M 480M 743M 790M 469M 285M
Cash flow detail
Operating cash flow (USD) 15.9M 41.2M 35.9M 98.4M 84M -68.1M 119M 146M 430M 569M
Purchases of property, plant and equipment (USD) -22.1M -77.2M -162M -164M -129M -112M -123M -75.6M -125M -192M
Purchases of intangible assets (USD) — -3.4M -5M -7.2M -37.5M -10.8M -34.4M -33.6M -9.1M -27.8M
Change in receivables (cash effect) (USD) 12.6M -26.3M -14.6M -10.8M -15.6M -71.3M -12.9M -99.4M — —
Change in inventories (cash effect) (USD) -24.1M 1.69M -38.8M -30.2M -50.5M -154M -49.1M -53.6M -32.4M -10.6M
Change in payables (cash effect) (USD) — — -5.4M 25.6M 7.1M -15.6M -2.4M -11M 2.2M 49.2M
Share buybacks (cash effect) (USD) — — — — — — — 0.00 0.00 -59.6M
Interest paid (cash effect) (USD) -3.69M -2.48M 0.00 0.00 -2.6M -21.5M -34.2M -49.9M -47.1M -50.8M
Income taxes paid (cash effect) (USD) -932,000 -462,000 -795,000 -2.5M -3M -7M -5.5M -8.1M -20.6M -38.5M
Share-based compensation (USD) 23.6M 31.9M 37.5M 28.7M 35.9M 34.4M 40.9M 48.3M 69.3M 62.7M
Operating cash flow before change in receivables (USD) 3.36M 67.5M 50.5M 109M 99.6M 3.2M 132M 245M — —
Free cash flow (OCF - PPE - intangibles) (USD) -6.2M -36M -126M -72.5M -82.5M -191M -38.3M 36.5M 296M 350M
Income detail
Research and development expense (USD) 55.7M 74.5M 88.6M 130M 147M 160M 180M 205M 220M 301M
↳ 5y CAGR +20.6% +25.0% +32.4% +36.0% +27.7% +23.5% +19.3% +18.3% +11.1% +15.5%
Total comprehensive income (USD) -29M -26.6M 880,000 13.3M 13.5M 9.1M 26.8M 194M 397M 273M
Comprehensive income to owners (USD) -29M -26.6M 880,000 13.3M 13.5M 9.1M 26.8M 194M 397M 273M
Provision for credit losses (USD) 2.07M 1.92M 3.38M 4.5M 3.3M 3.1M 4.2M 2.3M -200,000 700,000
Credit cost ratio (credit losses / average receivables) (%) 5.4% 4.7% 5.8% 6.8% 4.3% 2.5% 2.8% — — —
Reported Feb 28, 2017 Feb 26, 2020 Feb 24, 2021 Feb 24, 2021 Feb 24, 2021 Feb 24, 2022 Feb 24, 2023 Feb 18, 2026 Feb 18, 2026 May 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Insulet Reports Third Quarter 2026 Results Bull 5 Bear 0 Results

November 4, 2026

Third Quarter Revenue of $842 million, Increase of 19.2% (19.6% in Constant Currency1)

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2026.

Third Quarter Financial Highlights:

  • Revenue of $842.0 million, up 19.2%, or 19.6% in constant currency, slightly above the high end of the Company’s guidance range of 17.5% - 19.5% at constant currency rates
    • Total Omnipod revenue of $836.6 million, rose 19.7%, or 20.0% in constant currency
      • U.S. Omnipod revenue of $570.4 million, increased 14.7%
      • International Omnipod revenue of $266.2 million, increased 31.7%, or 33.0% in constant currency
    • Drug Delivery revenue of $5.5 million
  • Operating income of $189.8 million, or 22.5% of revenue, up 590 basis points over prior year
  • Adjusted operating income 1 of $185.2 million, or 22.0% of revenue, up 490 basis points compared to prior year
  • Net income of $141.1 million, or $2.03 per diluted share, compared to $87.6 million, or $1.24 per diluted share, in the prior year
  • Adjusted net income 1 of $138.0 million, increased 57.2% compared to $87.8 million in the prior year
  • Adjusted earnings 1 of $1.99 per diluted share, increased 59.9%, compared to $1.24 per diluted share, in the prior year

Recent Strategic Highlights:

  • Advanced commercial objectives, completing U.S. sales force expansion and executing Type 2 action plan by improving onboarding and customer support, enhancing sampling, and aligning sales force compensation with new customer start and retention goals
  • Completed full U.S. market release of Omnipod Discover ®, driving adoption by more than 35,000 users and 5,000 healthcare professionals across available markets 2, extending the reach of our proprietary engagement platform to deliver personalized insights and decision support to both people with diabetes and healthcare professionals strengthening engagement, improving outcomes, and increasing customer loyalty
  • Extended Omnipod 5 algorithm enhancement to full retail across the U.S., with real-world evidence showing better user outcomes with less effort
  • Extended Omnipod 5 Ecosystem with sensor choice by expanding Abbott’s FreeStyle Libre 3 Plus Continuous Glucose Monitor (CGM) integration across Belgium, Netherlands, UK, Italy, Finland, Norway, Sweden, Australia, Switzerland and Germany
  • Presented data at European Association for the Study of Diabetes (EASD) 2026 reinforcing our global clinical evidence
    • Omnipod 5 largest presentation of multinational real-world data to date, from more than 384,000 people with type 1 diabetes across 17 countries, demonstrating consistent time-in-range (TIR) outcomes 3
    • EVOLUTION 3 fully closed-loop feasibility study demonstrated adults with type 2 diabetes using both a GLP-1 and CGM saw additional TIR benefit from fully closed-loop automated insulin delivery with no user initiated boluses 4
  • Completed enrollment in two key clinical trials supporting our innovation pipeline:
    • STRIVE2 type 1 diabetes cohort, marking an important milestone in the advancement of Omnipod 6
    • EVOLVE pivotal study, supporting the development of fully closed-loop automated insulin delivery (AID) for adults with type 2 diabetes

Received approval from the Board of Directors for a $1 billion share repurchase program. The Company expects to allocate approximately $400 million toward repurchases in the fourth quarter of 2026, funded with existing cash. This expanded authorization reflects Insulet’s strong balance sheet and disciplined approach to capital deployment.

“Our team delivered a strong quarter, with revenue growth of nearly 20% and significant margin expansion,” said Ashley McEvoy, President and CEO. “We are making continued progress on our type 2 action plan, strengthening our commercial capabilities, expanding our customer base, increasing manufacturing scale and advancing innovation. As we look ahead, the business is well positioned for durable, profitable growth. The share repurchase we are announcing today demonstrates our confidence in the strength of the Omnipod platform and Insulet's long-term trajectory.”

_______________________
1 See description of non-GAAP financial measures contained in this release.
2 Omnipod Discover global users as of November 2, 2026.
3 Wilmot, E et al. Real-world performance of the Omnipod 5 AID system in children, adolescents, and adults with type 1 diabetes evidence from international markets presented at EASD 2026; October 1; Milan.
4 Boyd, J et al. Safety and performance of a fully closed-loop (FCL) algorithm for Omnipod in people with type 2 diabetes using GLP-1 RA; sub-analysis of the EVOLUTION3 study presented at EASD 2026; October 1; Milan.

2026 Outlook:

For the year ending December 31, 2026, the Company is providing the following guidance (revenue in constant currency):

FY 2026 Guidance(as of 11/4/2026) FY 2026 Prior Guidance(as of 8/5/2026)
U.S. Omnipod 17.5% - 18.5% 17% - 19%
International Omnipod 32% - 33% 30% - 32%
Total Omnipod 21.5% - 22.5% 21% - 23%
Drug Delivery ~(40%) ~(40%)
Total 21% - 22% 20% - 22%
Adjusted Operating Margin1 ~150 bps YoY expansion ~100 bps YoY expansion
Adjusted EPS Growth1 >30% >30%

Conference Call:

Insulet will host a conference call at 8:00 a.m. (Eastern Time) on November 4, 2026 to discuss the financial results and outlook. The link to the live call will be available on the Investor Relations section of the Company’s website at investors.insulet.com , “Events and Presentations,” and will be archived for future reference. The live call may also be accessed by dialing (833) 461-5787 for domestic callers or (585) 542-9983 for international callers, passcode 186 295 579.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com or omnipod.com .

Non-GAAP Measures:

The Company uses the following non-GAAP financial measures:

  • Constant currency revenue growth, which represents the change in revenue between current and prior-year periods using the exchange rate in effect during the applicable prior-year period. Insulet presents constant currency revenue growth because management believes it provides meaningful information regarding the Company’s results on a consistent and comparable basis across periods. Management uses this non-GAAP financial measure, in addition to financial measures in accordance with generally accepted accounting principles in the United States (GAAP), to evaluate the Company’s operating results. It is also one of the performance metrics that determines management incentive compensation.

  • Adjusted gross profit, adjusted gross margin, adjusted operating income, adjusted operating margin, adjusted net income, and adjusted diluted earnings per share exclude the impact of certain significant transactions or events, such as legal settlements, gains (losses) on investments and loss on extinguishment of debt, that affect the period-to-period comparability of the Company’s performance, as applicable.

  • Adjusted EBITDA, which represents net income plus net interest expense (income), income tax expense (benefit), depreciation and amortization, stock-based compensation expense, and other significant transactions or events that affect the period-to-period comparability of the Company’s performance, as applicable, and adjusted EBITDA as a percentage of revenue.

  • Free cash flow, defined as net cash provided by operating activities less capital expenditures. Management uses this non-GAAP measure, in addition to GAAP financial measures, to evaluate our operating results.

Insulet presents the above non-GAAP financial measures because management uses them as supplemental measures to assess the Company’s performance, and the Company believes they are helpful to investors and other interested parties in comparing the Company’s performance from period to period.

These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s financial results prepared in accordance with GAAP. Furthermore, the Company’s definition of these non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, Insulet strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety.

Forward-Looking Statement:

This press release contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials, approval of products by regulatory bodies, and achievement of reimbursement from third-party payors. These forward-looking statements are based on management’s current beliefs, assumptions and estimates and are not intended to be a guarantee of future events or performance. If management’s underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by the forward-looking statements.

Risks and uncertainties include, but are not limited to, international regulatory, commercial and logistics risks, including any expansion of tariffs; our dependence on a principal product platform; the impact of competitive products, technological change and product innovation; our ability to maintain an effective sales force and expand our distribution network; our ability to maintain and grow our customer base, including through expansion to additional international markets; our ability to scale the business to support revenue growth; our ability to secure and retain adequate coverage or reimbursement from third-party payors; the impact of healthcare reform laws; our ability to design, develop, manufacture and commercialize future products; unfavorable results of clinical studies, including issues with third parties conducting any studies, or future publication of articles or announcement of endorsements by diabetes associations or other organizations that are unfavorable; our ability to protect our intellectual property and other proprietary rights; potential conflicts with the intellectual property of third parties; our inability to maintain existing or enter into new license or other agreements with respect to continuous glucose monitors, data management systems or other rights necessary to sell our current products and/or commercialize future products; worldwide macroeconomic and geopolitical uncertainty, including the war with Iran, as well as risks associated with any future pandemic, including supply chain disruptions; the potential violation of anti-bribery/anti-corruption laws; the concentration of manufacturing operations and storage of inventory in a limited number of locations; the regulatory requirements and overall complexity in manufacturing our product and challenges associated with starting new manufacturing lines; supply disruptions or price fluctuations involving sole-source or third-party suppliers on which we are dependent; failure to retain key suppliers; challenges to the future development of our non-insulin drug delivery product line; our failure, or the failure of our contract manufacturer or component suppliers, to comply with the U.S. Food and Drug Administration’s quality system regulations, our or our contract manufacturer’s ability to successfully implement quality inspection systems, or other manufacturing difficulties; extensive government regulation applicable to medical devices, as well as complex and evolving privacy, data protection and artificial intelligence laws; adverse regulatory or legal actions relating to current or future Omnipod products; potential adverse impacts resulting from a recall, or discovery of product safety issues, including potential adverse impacts relating to our recent medical device corrections; breaches or failures of our product or information technology systems, including by cyberattack; our ability to maintain the privacy and security of Company and third-party information; our ability to attract, motivate, and retain key personnel; risks associated with potential future acquisitions or investments in new businesses; our ability to raise additional funds on acceptable terms or at all; restrictions imposed by our Credit Agreement; the volatility of the trading price of our common stock; and changes in tax laws or exposure to significant tax liabilities.

For a further list and description of these and other important risks and uncertainties that may affect the Company’s future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which the Company may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q the Company has filed or will file hereafter. Any forward-looking statement made in this release speaks only as of the date of this release. Insulet does not undertake to update any forward-looking statement, other than as required by law.

©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. All other trademarks are the property of their respective owners.

INSULET CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
Three Months Ended September 30, Nine Months Ended September 30,
(in millions, except share and per share data) 2026 2025 2026 2025
Revenue $ 842.0 $ 706.3 $ 2,405.4 $ 1,924.3
Cost of revenue 209.9 196.2 681.7 553.0
Gross profit 632.1 510.1 1,723.8 1,371.3
Research and development expenses 91.6 77.2 269.4 210.2
Selling, general and administrative expenses 350.7 315.2 1,012.8 833.6
Operating income 189.8 117.7 441.5 327.5
Interest expense, net (12.1 ) (7.0 ) (31.7 ) (15.5 )
Loss on extinguishment of debt (0.3 ) — (0.3 ) (123.9 )
Other (expense) income, net (0.2 ) 12.1 (0.7 ) 11.2
Income before income taxes 177.2 122.8 408.9 199.3
Income tax expense (36.1 ) (35.2 ) (81.7 ) (53.9 )
Net income $ 141.1 $ 87.6 $ 327.1 $ 145.5
Earnings per share:
Basic $ 2.03 $ 1.24 $ 4.70 $ 2.07
Diluted $ 2.03 $ 1.24 $ 4.69 $ 2.05
Weighted-average number of common shares outstanding (in thousands):
Basic 69,359 70,367 69,548 70,343
Diluted 69,492 70,661 69,699 72,292
RECONCILIATION OF DILUTED NET INCOME (UNAUDITED)
Three Months Ended September 30, Nine Months Ended September 30,
(in millions) 2026 2025 2026 2025
Net income $ 141.1 $ 87.6 $ 327.1 $ 145.5
Add back interest expense, net of tax attributable to assumed conversion of convertible notes — — — 2.8
Net income, diluted $ 141.1 $ 87.6 $ 327.1 $ 148.3

Note: Columns may not add due to rounding. Earnings per share is calculated using actual, non-rounded amounts and, therefore, may not recalculate from the amounts presented.

INSULET CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(in millions) September 30, 2026 December 31, 2025
ASSETS
Cash and cash equivalents $ 584.4 $ 716.1
Accounts receivable, net 689.0 516.9
Inventories 552.1 452.6
Prepaid expenses and other current assets 216.0 228.3
Total current assets 2,041.5 1,914.0
Property, plant and equipment, net 918.6 819.5
Other intangible assets, net 114.8 117.1
Goodwill 51.6 51.6
Other assets 288.6 288.2
Total assets $ 3,415.1 $ 3,190.4
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable $ 162.2 $ 75.0
Accrued expenses and other current liabilities 633.1 586.7
Current portion of long-term debt 19.1 18.4
Total current liabilities 814.4 680.1
Long-term debt, net 943.0 930.8
Other liabilities 78.6 64.4
Total liabilities 1,836.0 1,675.2
Stockholders' equity 1,579.1 1,515.2
Total liabilities and stockholders’ equity $ 3,415.1 $ 3,190.4

Note: Columns may not add due to rounding.

INSULET CORPORATIONNON-GAAP RECONCILIATIONS (UNAUDITED)CONSTANT CURRENCY REVENUE GROWTH
Three Months Ended September 30,
(dollars in millions) 2026 2025 Percent Change Currency Impact Constant Currency
U.S. $ 570.4 $ 497.1 14.7 % — % 14.7 %
International 266.2 202.1 31.7 % (1.3 )% 33.0 %
Total Omnipod Products 836.6 699.2 19.7 % (0.4 )% 20.0 %
Drug Delivery 5.5 7.1 (22.7 )% — % (22.7 )%
Total $ 842.0 $ 706.3 19.2 % (0.4 )% 19.6 %
Nine Months Ended September 30,
(dollars in millions) 2026 2025 Percent Change Currency Impact Constant Currency
U.S. $ 1,630.1 $ 1,352.0 20.6 % — % 20.6 %
International 760.8 540.2 40.8 % 4.4 % 36.4 %
Total Omnipod Products 2,390.9 1,892.2 26.4 % 1.3 % 25.1 %
Drug Delivery 14.6 32.2 (54.7 )% — % (54.7 )%
Total $ 2,405.4 $ 1,924.3 25.0 % 1.2 % 23.8 %

Note: Columns may not add due to rounding. Percentages are calculated using actual, non-rounded amounts and, therefore, may not recalculate from the amounts presented.

INSULET CORPORATIONNON-GAAP RECONCILIATIONS (UNAUDITED)2026 ADJUSTED OPERATING INCOME, NET INCOME & DILUTED EPS
Three Months Ended September 30, 2026
(in millions) Gross Profit Gross Margin Operating Income Operating Margin Income before income taxes Net Income(4) Diluted Earnings per Share Effective Tax Rate
GAAP $ 632.1 75.1 % $ 189.8 22.5 % $ 177.2 $ 141.1 $ 2.03 20.4 %
Voluntary MDCs and related costs(1) (7.2 ) (4.5 ) (4.5 ) (3.6 ) (0.05 )
Loss on extinguishment of debt(2) — — 0.3 0.2 —
Tax matters(3) — — — 0.3 —
Non-GAAP $ 624.9 74.2 % $ 185.2 22.0 % $ 172.9 $ 138.0 $ 1.99 20.2 %
Nine Months Ended September 30, 2026
(in millions) Gross Profit Gross Margin Operating Income Operating Margin Income before income taxes Net Income(4) Diluted Earnings per Share Effective Tax Rate
GAAP $ 1,723.8 71.7 % $ 441.5 18.4 % $ 408.9 $ 327.1 $ 4.69 20.0 %
Voluntary MDCs and related costs(1) 26.4 32.2 32.2 25.6 0.37
CFO transition costs(5) — (0.5 ) (0.5 ) (0.4 ) (0.01 )
Loss on extinguishment of debt(2) — — 0.3 0.2 —
Tax matters(3) — — — 0.2 —
Non-GAAP $ 1,750.1 72.8 % $ 473.2 19.7 % $ 440.9 $ 352.8 $ 5.06 20.0 %
(1) Represents the net impact of adjustments to estimated warranty and related costs associated with the voluntary medical device corrections (MDCs) issued in March and May 2026.
(2) Relates to the repricing of our Term Loan B.
(3) Primarily represents a consolidating effective tax rate adjustment related to non-GAAP items and excess tax benefits from employee share-based compensation.
(4) The tax effect on non-GAAP adjustments is calculated based on applicable local statutory rates.
(5) Represents an adjustment to severance benefits for the Company's former Chief Financial Officer (CFO).

Note: Columns may not add due to rounding. Diluted earnings per share and effective tax rates are calculated using actual, non-rounded amounts and, therefore, may not recalculate from the amounts presented.

INSULET CORPORATIONNON-GAAP RECONCILIATIONS (UNAUDITED) (CONTINUED)2025 ADJUSTED OPERATING INCOME, NET INCOME & DILUTED EPS
Three Months Ended September 30, 2025
(in millions, except per share data) Operating Income Operating Margin Income before Income Taxes Net Income(4) Net Income, Diluted Diluted Earnings per Share Effective Tax Rate
GAAP $ 117.7 16.7 % $ 122.8 $ 87.6 $ 87.6 $ 1.24 28.7 %
CFO transition costs(1) 3.0 3.0 2.9 2.9 0.04
Gain on derivative asset(2) — (12.5 ) (12.5 ) (12.5 ) (0.18 )
Tax matters(3) — — 9.8 9.8 0.14
Non-GAAP $ 120.7 17.1 % $ 113.3 $ 87.8 $ 87.8 $ 1.24 22.5 %
Nine Months Ended September 30, 2025
(in millions) Operating Income Operating Margin Income before income taxes Net Income(4) Net Income, Diluted Diluted Earnings per Share Effective Tax Rate
GAAP $ 327.5 17.0 % $ 199.3 $ 145.5 $ 148.3 $ 2.05 27.0 %
CEO and CFO transition costs(1) (2.3 ) (2.3 ) (2.6 ) (2.6 ) (0.04 )
Losses on investments(5) 4.7 7.5 5.8 5.8 0.08
Loss on extinguishment of debt(6) — 123.9 123.1 123.1 1.70
Gain on derivative asset(2) — (12.5 ) (12.5 ) (12.5 ) (0.17 )
Tax matters(3) — — (14.0 ) (14.0 ) (0.19 )
Non-GAAP $ 329.9 17.1 % $ 315.9 $ 245.2 $ 248.0 $ 3.43 22.4 %
(1) The amount for the three months ended September 30, 2025 represents severance benefits associated with the departure of the Company's former CFO, net of forfeiture of equity awards. The amount for the nine months ended September 30, 2025 represents the forfeiture of equity awards by the Company's former Chief Executive Officer (CEO) and CFO, net of severance benefits.
(2) Represents the change in fair value of the derivative asset associated with the redemption of our convertible notes.
(3) Primarily represents a consolidating effective tax rate adjustment related to non-GAAP items and excess tax benefits from employee share-based compensation.
(4) The tax effect on non-GAAP adjustments is calculated based on applicable local statutory rates.
(5) Represents a provision for credit losses on a debt investment, included in selling, general and administrative expenses, and an impairment of an equity investment, included in other expense.
(6) Relates to the repurchase of convertible notes.

Note: Columns may not add due to rounding. Diluted earnings per share and effective tax rates are calculated using actual, non-rounded amounts and, therefore, may not recalculate from the amounts presented.

INSULET CORPORATIONNON-GAAP RECONCILIATIONS (UNAUDITED) (CONTINUED)ADJUSTED EBITDA
Three Months Ended September 30, Nine Months Ended September 30,
(in millions) 2026 Percent of Revenue 2025 Percent of Revenue 2026 Percent of Revenue 2025 Percent of Revenue
Net income $ 141.1 16.8 % $ 87.6 12.4 % $ 327.1 13.6 % $ 145.5 7.6 %
Interest expense, net 12.1 7.0 31.7 15.5
Income tax expense 36.1 35.2 81.7 53.9
Depreciation and amortization 28.2 22.0 81.1 66.0
Stock-based compensation expense(1) 20.5 16.7 61.5 42.4
Voluntary MDCs and related costs(2) (4.5 ) — 32.2 —
CFO and CEO transitions(3) — 4.0 (0.5 ) 9.4
Loss on extinguishment of debt(4) 0.3 — 0.3 123.9
Gain on derivative asset(5) — (12.5 ) — (12.5 )
Losses on investments(6) — — — 7.5
Adjusted EBITDA $ 233.7 27.7 % $ 160.0 22.7 % $ 615.1 25.6 % $ 451.5 23.5 %
(1) Amounts for the three and nine months ended September 30, 2025 include reversals of stock-based compensation expense associated with the departures of the Company’s former CFO and CEO totaling $1.0 million and $11.7 million, respectively.
(2) Represents the net impact of adjustments to estimated warranty and related costs associated with the voluntary MDCs issued in March and May 2026.
(3) Amount for the nine months ended September 30, 2026 represents adjustments to severance benefits for the Company’s former CFO. The amounts for the three and nine months ended September 30, 2025 represent the severance expenses related to the departure of the Company’s former CFO and CEO.
(4) Amounts for the three and nine months ended September 30, 2026 relate to the refinancing of our Term Loan B. The amount for the nine months ended September 30, 2025 relates to the repurchase of convertible notes.
(5) Represents the change in fair value of the derivative asset associated with the redemption of our convertible notes.
(6) Represents losses associated with debt and equity investments.
FREE CASH FLOW
Nine Months Ended September 30,
(in millions) 2026 2025
Net cash provided by operating activities $ 325.7 $ 386.0
Capital expenditures (113.9 ) (56.5 )
Free cash flow $ 211.7 $ 329.5

Note: Columns may not add due to rounding. Percentages are calculated using actual, non-rounded amounts and, therefore, may not recalculate from the amounts presented.

INSULET CORPORATIONNON-GAAP RECONCILIATIONS (UNAUDITED) CONTINUEDREVENUE GUIDANCE
Year Ending December 31, 2026
Revenue GrowthGAAP Currency Impact Constant Currency
U.S. Omnipod 17.5% - 18.5% —% 17.5% - 18.5%
International Omnipod 35% - 36% 3% 32% - 33%
Total Omnipod 22.5% - 23.5% 1% 21.5% - 22.5%
Drug Delivery ~(40.0%) —% ~(40%)
Total 22% - 23% 1% 21% - 22%

Investor Relations:
Clare Trachtman
Vice President, Investor Relations
[email protected]

Media:
Joan Campion
Vice President, External Communications
[email protected]

Source: Insulet Corporation

Multimedia Files:

View All News

Contact Us

Clare Trachtman
Vice President, Investor Relations

[email protected]

Quick Links

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Insulet Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Insulet Corporation to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

Press Releases
Quarterly Reports
Annual Reports
All SEC Filings
Daily Stock Quote
Events & Presentations

Submit Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

Insulet Corporation Logo

Follow us on LinkedIn

© 2024 Insulet Corporation. All rights reserved.

Cookies Button

This website uses cookies

We use cookies to personalise content and to analyse our traffic. We also share information about your use of our site with our analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. By clicking “Accept all cookies”, you agree to the storing of cookies on your device to enhance site navigation and analyse site usage. By clicking on "Cookie settings" you can change your cookie preferences.

Accept all cookies

Reject optional cookies

Cookie settings

Company Logo

Continue without accepting

Privacy cookie settings

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.
More information

Accept all cookies

Manage cookie settings

Strictly necessary cookies

Always on

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.

View Vendor Details

Optional cookies

Optional cookies Off

  • Performance cookies

    Switch Label label

    These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

  • Functional cookies

    Switch Label label

    Functional cookies are used to create technologically advanced and user-friendly websites that adapt automatically to your needs and preferences. These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

View Vendor Details

Back Button

Vendors List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject optional cookies Confirm

Powered by Onetrust

November 3, 2026

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in London on Wednesday, November 18, 2026, at 10:30 a.m. (GMT).

The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events .

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com or omnipod.com .

©2026 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.

Investor Relations:
Clare Trachtman
Vice President, Investor Relations
[email protected]

Media:
Joan Campion
Vice President, External Communications
[email protected]

Source: Insulet Corporation

Multimedia Files:

View All News

Contact Us

Clare Trachtman
Vice President, Investor Relations

[email protected]

Quick Links

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Insulet Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Insulet Corporation to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

Press Releases
Quarterly Reports
Annual Reports
All SEC Filings
Daily Stock Quote
Events & Presentations

Submit Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

Insulet Corporation Logo

Follow us on LinkedIn

© 2024 Insulet Corporation. All rights reserved.

Cookies Button

This website uses cookies

We use cookies to personalise content and to analyse our traffic. We also share information about your use of our site with our analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. By clicking “Accept all cookies”, you agree to the storing of cookies on your device to enhance site navigation and analyse site usage. By clicking on "Cookie settings" you can change your cookie preferences.

Accept all cookies

Reject optional cookies

Cookie settings

Company Logo

Continue without accepting

Privacy cookie settings

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.
More information

Accept all cookies

Manage cookie settings

Strictly necessary cookies

Always on

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.

View Vendor Details

Optional cookies

Optional cookies Off

  • Performance cookies

    Switch Label label

    These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

  • Functional cookies

    Switch Label label

    Functional cookies are used to create technologically advanced and user-friendly websites that adapt automatically to your needs and preferences. These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

View Vendor Details

Back Button

Vendors List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject optional cookies Confirm

Powered by Onetrust

Insulet Announces Omnipod Discover Now Available in U.S. Bull 2 Bear 0 Product/operations

October 12, 2026

Web-based data platform turns Omnipod 5 data into clear, personalized insights for users, caregivers, and healthcare professionals

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. full market release of Omnipod Discover**™**, a web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers (HCPs). Omnipod Discover turns critical diabetes data into clear visualizations and personalized insights, giving people with diabetes and their HCPs a shared understanding of therapy patterns to make more informed diabetes management decisions.

"The future of diabetes care is not just about generating more data, it's about making that data meaningful,” said Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Chief Medical Officer at Insulet. “Omnipod Discover simplifies data review for Omnipod 5 users and their healthcare providers so they spend less time gathering information and more time collaborating on diabetes management."

With Omnipod Discover, Omnipod 5 users get simple, personalized glucose and insulin delivery reports sent directly to their smartphone weekly, so they know where to focus their diabetes management efforts. Omnipod Discover also helps HCPs make confident clinical recommendations from a concise report by overlaying a licensed Ambulatory Glucose Profile (AGP) with key adjustable pump settings and bolus events.

Omnipod Discover has already been adopted in the United States by more than 15,000 Omnipod 5 users and over 1,800 healthcare professionals as part of Insulet's limited market release program in the U. S. It is also available to users and HCPs in Spain, Australia, Saudi Arabia, Qatar, Kuwait, UAE, and Israel.

"In today's AID (automated insulin delivery) era, clinicians need actionable insights, not more data. Omnipod Discover brings key diabetes metrics and insights together in a streamlined, easy-to-use workflow that supports clinical decision-making and patient conversations,” said Dr. Martin Sarkar, DO, ECNU, Endocrinologist at EndoCARE Diabetes & Wellness Center in Frederick, Maryland. “It also gives people with diabetes greater visibility into their therapy, helping foster engagement and trust. Omnipod Discover is an important step toward a more connected diabetes ecosystem that supports both providers and patients."

In June, Insulet presented Real-World Glycemic Outcomes1 using the Omnipod Discover platform at the American Diabetes Association’s Scientific Sessions in New Orleans, Louisiana. Use of Omnipod Discover was associated with improvements in time in range (TIR), with 32% of users seeing a clinically meaningful increase in TIR of 3% or more. These findings support the vital role that user engagement with Omnipod Discover can play in diabetes self-management.

The platform is now available to all Omnipod 5 users nationwide, with healthcare professionals able to enroll through onboarding and training provided by their dedicated Omnipod sales representative.

To enroll in Omnipod Discover, Omnipod 5 users can log into PodderCentral and follow the on-screen prompts. Healthcare professionals can visit our website to learn more or contact their dedicated Omnipod sales representative.

_1 Mora, PF, et al. Real-World Glycemic Outcomes Using the Omnipod Discover Data Management System. Diabetes 1 June 2026; 75 (Supplement 1): 2887–LB. https://doi.org/10.2337/db26-2887-LB _

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, visit insulet.com or omnipod.com .

©2026 Insulet Corporation. Omnipod, Omnipod Discover and PodderCentral are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved.

Investor Relations:
Clare Trachtman
Vice President, Investor Relations
[email protected]

Media:
Joan Campion
Vice President, External Communications
[email protected]

Source: Insulet Corporation

Multimedia Files:

View All News

Contact Us

Clare Trachtman
Vice President, Investor Relations

[email protected]

Quick Links

Investor Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Insulet Corporation, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Insulet Corporation to send you the requested Investor Email Alert updates.

* Required

Email Address *

Investor Alert OptionsInvestor Alert Options *

Press Releases
Quarterly Reports
Annual Reports
All SEC Filings
Daily Stock Quote
Events & Presentations

Submit Sign Up

Unsubscribe

Email Alert Sign Up Confirmation

Insulet Corporation Logo

Follow us on LinkedIn

© 2024 Insulet Corporation. All rights reserved.

Cookies Button

This website uses cookies

We use cookies to personalise content and to analyse our traffic. We also share information about your use of our site with our analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services. By clicking “Accept all cookies”, you agree to the storing of cookies on your device to enhance site navigation and analyse site usage. By clicking on "Cookie settings" you can change your cookie preferences.

Accept all cookies

Reject optional cookies

Cookie settings

Company Logo

Continue without accepting

Privacy cookie settings

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.
More information

Accept all cookies

Manage cookie settings

Strictly necessary cookies

Always on

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.

View Vendor Details

Optional cookies

Optional cookies Off

  • Performance cookies

    Switch Label label

    These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

  • Functional cookies

    Switch Label label

    Functional cookies are used to create technologically advanced and user-friendly websites that adapt automatically to your needs and preferences. These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

View Vendor Details

Back Button

Vendors List

Search Icon

Filter Icon

Clear

  • checkbox label label

Apply Cancel

Consent Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Reject optional cookies Confirm

Powered by Onetrust

Prompts

Insulet Corporation (ticker PODD), listed in United States.

ETFs Holding Insulet Corporation

ETF Weight in ETF Shares Market value As of
LGHT 4.44% 721 $ 109.772K Jun 30, 2026
NLSI 3.89% 1,354 $ 176.656K Sep 30, 2026
TMED 2.38% 3,601 $ 548.252K Jun 30, 2026
SAGP 1.89% 9,515 $ 1.449M Jun 30, 2026
CPAI 1.88% 45,459 $ 6.921M Jun 30, 2026
TMAT 1.07% 15,403 $ 2.547M Jul 31, 2026
DWSH short -0.88% -373 $ -54.212K Nov 17, 2026
SEIM 0.66% 65,415 $ 9.959M Jun 30, 2026
TCAL 0.50% 11,400 $ 1.656M Nov 17, 2026
HRTS 0.49% 1,827 $ 271.602K Aug 31, 2026
WCEO 0.48% 292 $ 48.282K Jul 31, 2026
SYZ 0.35% 1,571 $ 239.185K Jun 30, 2026
MKTN 0.34% 2,372 $ 361.137K Jun 30, 2026
SGLC 0.31% 4,495 $ 668.227K Aug 31, 2026
VFQY 0.22% 7,710 $ 1.146M Aug 31, 2026
FMDE 0.21% 103,282 $ 15.725M Jun 30, 2026
GQI 0.16% 2,730 $ 415.643K Jun 30, 2026
FEMG 0.11% 50 $ 7,612.50 Jun 30, 2026
IALT short -0.11% -61,793 $ -8.978M Nov 16, 2026
AVMV 0.10% 5,601 $ 813.769K Nov 16, 2026
FTQI 0.10% 6,553 $ 952.085K Nov 16, 2026
AVMC 0.09% 3,609 $ 524.352K Nov 16, 2026
DFAS 0.07% 167,657 $ 25.03M Nov 12, 2026
MSSM 0.06% 2,964 $ 440.628K Aug 31, 2026
FEAC 0.06% 104 $ 15.834K Jun 30, 2026
JSTC 0.06% 1,236 $ 179.578K Nov 17, 2026
FLCG 0.05% 2,121 $ 315.308K Aug 31, 2026
CAPE 0.05% 765 $ 116.471K Jun 30, 2026
AVUQ 0.04% 1,068 $ 155.17K Nov 16, 2026
DFSU 0.03% 5,400 $ 806.166K Nov 12, 2026
FLCC 0.03% 293 $ 43.557K Aug 31, 2026
DFAC 0.02% 100,462 $ 14.998M Nov 12, 2026
NTSX 0.02% 1,472 $ 224.112K Jun 30, 2026
HCMT 0.01% 480 $ 79.368K Jul 31, 2026
GDE 0.01% 400 $ 59.464K Aug 31, 2026
AVUS 0.01% 6,274 $ 911.549K Nov 16, 2026
AVLV 0.01% 12,184 $ 1.77M Nov 16, 2026
AVLC 0.01% 1,310 $ 190.33K Nov 16, 2026
GSPY 0.01% 471 $ 68.432K Nov 17, 2026
MSLC 0.01% 2,670 $ 396.922K Aug 31, 2026
VOXP 0.01% 3 $ 496.05 Jul 31, 2026
DCOR 0.01% 22,795 $ 3.403M Nov 12, 2026
VSLU 0.01% 264 $ 40.194K Jun 30, 2026
DFUS 0.01% 10,297 $ 1.537M Nov 12, 2026
DXUV 0.01% 2,669 $ 398.455K Nov 12, 2026
DFAU 0.00% 2,582 $ 385.467K Nov 12, 2026
NTSD 0.00% 6 $ 913.50 Jun 30, 2026
DFUV 0.00% 23 $ 3,433.67 Nov 12, 2026
CSHP 0.00% 109 $ 15.837K Nov 16, 2026
AVSU 0.00% 144 $ 20.922K Nov 16, 2026
CORO 0.00% 44 $ 6,351.82 Nov 16, 2026